Dr. Reddy's Laboratories Limited — PPTs, 22-07-2026: Investor Presentation

Here's the concise, retail-friendly summary:

**1. Business Performance:**

Dr. Reddy's reported Q1 FY27 revenues of ₹8,071 Cr (up 6% YoY) and a net profit of ₹443 Cr (up 69% YoY). The core business achieved healthy double-digit growth, though a significant ₹240 Cr impact from semaglutide API issues affected overall margins. Growth was strong across North America (+35% YoY), Emerging Markets (+31% YoY), and India (+17% YoY), with India outperforming the market.

**2. Growth Drivers or Strategy:**

Strategic focus includes strengthening core businesses, developing future growth areas like peptides and biosimilars, and advancing key products such as semaglutide. The company aims to enhance capabilities, drive operational efficiencies, and leverage M&A for organic growth.

**3. Recent Developments:**

Key recent achievements include a first-to-market US launch of generic bosutinib (anti-cancer drug) with exclusivity, and being the first to launch generic semaglutide injection in Canada and tablets in India. New nutrition offerings (Celevida GLP+ with Nestlé) and a successful oncology drug (Toripalimab, exceeding ₹100 Cr in sales) were also highlighted. However, the company received a Form 483 with 7 observations at its biologics facility and faced issues with semaglutide API batches.

**4. Key Financial Metrics:**

Diluted EPS stood at ₹5.3. Reported EBITDA margin was 12.5% (15.4% excluding semaglutide API impact). The company maintains a strong net cash surplus of ₹3,058 Cr.

**5. Management Commentary / Outlook:**

Management emphasized a diversified business model with broad growth levers and a continued focus on sustaining profitability while investing for future opportunities.